NEW YORK (GenomeWeb News) – Affymetrix yesterday reported modest fourth-quarter revenue growth, while its profits soared 47 percent for the three-month period ended Dec. 31, 2007.
 
The firm reported Q4 revenues of $107.6 million, a 3.3 percent increase over revenues of $104.2 million in the fourth quarter of 2006.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.